Skip to main content

Chronic Migraine News (Page 2)

Related terms: Migraine, Chronic

AAN: Prophylactic Zonisamide Effective in Pediatric Migraine

MONDAY, March 3, 2025 – For pediatric patients with migraine, prophylactic zonisamide use can significantly reduce the median number of headache days per month (HDPM), according to a study scheduled...

ACP Issues Clinical Guideline for Pharmacologic Prevention of Episodic Migraine

MONDAY, Feb. 10, 2025 – In a clinical guideline issued by the American College of Physicians and published online Feb. 4 in the Annals of Internal Medicine, recommendations are presented regarding...

Minority Children Less Likely to Be Diagnosed With Migraine in Emergency Department

WEDNESDAY, Feb. 5, 2025 – Compared with non-Hispanic White (NHW) children, non-Hispanic Black (NHB) and Hispanic/Latino (HL) children with a headache diagnosis in the emergency department have lower...

Too Often, ER Docs Don't Spot Migraines in Minority Kids

THURSDAY, Feb. 6, 2025 – Kids and teens can also get migraines, but Black and Hispanic children seen in ERs are more likely to have their condition go undiagnosed, new research shows. That's...

FDA Approves Symbravo for Acute Treatment of Migraine in Adults

WEDNESDAY, Feb. 5, 2025 – The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. The approval was ...

Beta Blocker Propranolol Might Reduce Migraine Stroke Risk

MONDAY, Feb. 3, 2025 – A common drug used to prevent migraines might have an additional benefit – protecting women against stroke. Women taking the beta blocker propranolol to ward off migraines...

Propranolol May Reduce Overall Stroke Risk in Women With Migraine

FRIDAY, Jan. 31, 2025 – Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke, according to a study...

Quick Fix? New Migraine Medicine, Qulipta, May Start Working Right Away

THURSDAY, Dec. 26, 2024 – Migraine patients often suffer a long time before docs zero in on the best dosage for drugs designed to prevent their terrible symptoms. But a recently approved daily...

Atogepant Superior for Efficacy, Functional Measures in Migraine

THURSDAY, Dec. 26, 2024 – For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research...

Clinical Practice Guideline Updated for Migraine, Tension-Type Headache

TUESDAY, Oct. 29, 2024 – In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Oct. 29 in the Annals of...

Study Addresses Differentiating Meniere Disease, Vestibular Migraine

THURSDAY, Oct. 3, 2024 – The dissociation between pathological caloric testing and a normal video head impulse test can differentiate between Meniere disease (MD) and vestibular migraine (VM),...

Review Compares Drug Interventions for Acute Migraine Treatment

MONDAY, Sept. 23, 2024 – All active interventions show superior efficacy to placebo for freedom from pain, and most do for sustained pain freedom, for the acute treatment of migraine among adults,...

Erenumab Effective for Nonopioid Medication Overuse Headache in Chronic Migraine

WEDNESDAY, Sept. 18, 2024 – Monthly use of erenumab injections (140 mg) is safe and effective in achieving medication overuse headache (MOH) remission in patients with nonopioid chronic migraine...

U.S. FDA Approves Qulipta (atogepant) for Adults With Chronic Migraine

NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Migraine

Related drug support groups

propranolol, Botox, Qulipta